NASDAQ:MNOV

MediciNova Q2 2026 Earnings Results & Report

MediciNova logo
$1.28 -0.05 (-3.83%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MediciNova beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.05 versus the -$0.0633 consensus estimate, while revenue of $458.44 thousand topped the $75 thousand estimate by $383.44 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

MediciNova EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.0633
Beat/Miss
Beat by +$0.0133
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

MediciNova Revenue Results

Actual Revenue
$458.44 thousand
Expected Revenue
$75 thousand
Beat/Miss
Beat by +$383.44 thousand
YoY Revenue Growth
N/A

Earnings Documents

MediciNova Q2 2026 Earnings FAQ

MediciNova (NASDAQ:MNOV) reported earnings of -$0.05 per share for Q2 2026, beating the consensus estimate of -$0.0633. The report was announced on Thursday, August 13, 2026.

MediciNova reported revenue of $458.44 thousand for Q2 2026, against a consensus estimate of $75 thousand.

MediciNova Earnings Headlines

Medicinova Inc
MediciNova to Participate in the Maxim Growth Summit
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries.

Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines.

MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.

View MediciNova Profile